Nuvectis Pharma, Inc. to Post FY2028 Earnings of $3.90 Per Share, Roth Capital Forecasts (NASDAQ:NVCT)

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities research analysts at Roth Capital boosted their FY2028 EPS estimates for Nuvectis Pharma in a report issued on Tuesday, May 7th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $3.90 per share for the year, up from their previous forecast of $3.59. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.52) per share.

Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Nuvectis Pharma in a report on Wednesday.

Nuvectis Pharma Stock Down 0.8 %

NASDAQ:NVCT opened at $6.38 on Thursday. The firm has a market capitalization of $117.21 million, a P/E ratio of -4.46 and a beta of 0.45. Nuvectis Pharma has a 52 week low of $5.92 and a 52 week high of $18.65. The company has a fifty day moving average of $8.10 and a 200 day moving average of $8.20.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01).

Insider Activity

In other news, CEO Ron Bentsur purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were bought at an average cost of $10.29 per share, for a total transaction of $51,450.00. Following the completion of the transaction, the chief executive officer now directly owns 3,242,484 shares of the company’s stock, valued at approximately $33,365,160.36. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 38.85% of the company’s stock.

Hedge Funds Weigh In On Nuvectis Pharma

Large investors have recently made changes to their positions in the business. Blue Zone Wealth Advisors LLC purchased a new position in Nuvectis Pharma during the first quarter valued at $118,000. Edmond DE Rothschild Holding S.A. bought a new position in shares of Nuvectis Pharma during the fourth quarter valued at $160,000. Strs Ohio raised its position in shares of Nuvectis Pharma by 59.0% in the 4th quarter. Strs Ohio now owns 6,200 shares of the company’s stock worth $51,000 after purchasing an additional 2,300 shares during the last quarter. Finally, Baldwin Brothers LLC MA grew its position in Nuvectis Pharma by 22.0% during the 4th quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock valued at $1,185,000 after purchasing an additional 25,660 shares during the last quarter. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.